How would you define the success of LGC's Oligonucleotide Synthesis platform?

Introduction

Defining the success of LGC's Oligonucleotide Synthesis platform requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge effectively, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

LGC's Oligonucleotide Synthesis platform is a specialized tool for creating custom DNA and RNA sequences used in genomics research, diagnostics, and therapeutics. Key stakeholders include:

1. Research scientists: Seeking high-quality, customized oligos for experiments
2. Pharmaceutical companies: Requiring large-scale oligo production for drug development
3. Diagnostic companies: Needing reliable oligos for test development
4. LGC management: Aiming to grow market share and profitability

User flow typically involves:

1. Sequence design: Users input desired oligo sequences through a web interface
2. Customization: Selection of modifications, purification methods, and scales
3. Order placement: Submission of synthesized oligo requests
4. Production: Automated synthesis of requested sequences
5. Quality control: Verification of oligo purity and accuracy
6. Delivery: Shipment of synthesized oligos to customers

This platform is crucial to LGC's strategy in the genomics market, positioning the company as a leading provider of high-quality, custom oligonucleotides. Compared to competitors like IDT and Eurofins, LGC aims to differentiate through superior automation, scalability, and customization options.

In terms of product lifecycle, the Oligonucleotide Synthesis platform is in the growth stage, with increasing demand driven by advancements in genomics research and personalized medicine.